ADAR1 Capital Management’s Structure Therapeutics GPCR Stock Holding History

ADAR1 Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,200	Closed	-$426K	–	277
2025 Q3	$426K	Buy	15,200 +200	+1%	+$3.98K	0.04%	147
2025 Q2	$311K	Sell	15,000 -20,619	-58%	-$453K	0.05%	136
2025 Q1	$617K	Buy	35,619 +300	+0.8%	+$7.35K	0.11%	92
2024 Q4	$958K	Buy	+35,319	New	+$1.25M	0.19%	80
2024 Q3	–	Sell	-1,516	Closed	-$59.5K	–	306
2024 Q2	$59.5K	Sell	1,516 -984	-39%	-$40.4K	0.01%	186
2024 Q1	$107K	Sell	2,500 -1,500	-38%	-$63.3K	0.02%	148
2023 Q4	$163K	Buy	+4,000	New	+$229K	0.06%	87

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ADAR1 Capital Management's GPCR Position: Q4 2025 in Review

ADAR1 Capital Management sold out of Structure Therapeutics (GPCR) in Q4 2025, closing a stake of 15,200 shares — an estimated $426K sold.

ADAR1 Capital Management first reported a position in GPCR in Q4 2023 and held it in 7 quarters. The position peaked at $958K in Q4 2024. 197 funds tracked by Wall St. Rank hold GPCR as of Q4 2025.

ADAR1 Capital Management reported no remaining Structure Therapeutics position as of Q4 2025 after selling out during the quarter.
ADAR1 Capital Management sold 15,200 Structure Therapeutics shares in Q4 2025, an estimated $426K.
ADAR1 Capital Management first reported a position in Structure Therapeutics in Q4 2023 and held it in 7 quarters.
ADAR1 Capital Management's Structure Therapeutics position peaked at $958K in Q4 2024.
197 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2025.

Based on ADAR1 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.